Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma
about
CD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin's LymphomasChimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and ProspectsAdoptive T-cell therapies for refractory/relapsed leukemia and lymphoma: current strategies and recent advancesPreclinical validation of interleukin 6 as a therapeutic target in multiple myelomaDesigning chimeric antigen receptors to effectively and safely target tumorsPreserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab.Strategies to genetically engineer T cells for cancer immunotherapy.In Vivo Murine-Matured Human CD3+ Cells as a Preclinical Model for T Cell-Based Immunotherapies.Clinical development of anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.Targeting CD8+ T-cell tolerance for cancer immunotherapy.Improving the safety of cell therapy products by suicide gene transferCMVpp65 Vaccine Enhances the Antitumor Efficacy of Adoptively Transferred CD19-Redirected CMV-Specific T Cells.Seatbelts in CAR therapy: How Safe Are CARS?The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity.CD19-CAR trials.Global Manufacturing of CAR T Cell Therapy.The inducible caspase-9 suicide gene system as a "safety switch" to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells.Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.Synthetic biology in cell-based cancer immunotherapy.Chimeric antigen receptor T-cell therapies for lymphoma.CAR T-cell immunotherapy: The path from the by-road to the freeway?Current status and regulatory perspective of chimeric antigen receptor-modified T cell therapeutics.Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy.Driving gene-engineered T cell immunotherapy of cancer.Spotlight on chimeric antigen receptor engineered T cell research and clinical trials in China.Design of chimeric antigen receptors with integrated controllable transient functions.CD20-targeting in B-cell malignancies: novel prospects for antibodies and combination therapies.Preclinical targeting of human T-cell malignancies using CD4-specific chimeric antigen receptor (CAR)-engineered T cells.Engineered T cells: the promise and challenges of cancer immunotherapy.How Chimeric Antigen Receptor Design Affects Adoptive T Cell Therapy.Management of patients with non-Hodgkin's lymphoma: focus on adoptive T-cell therapy.Chimeric Antigen Receptor T cells for B Cell Neoplasms: Choose the Right CAR for You.Engineering Therapeutic T Cells: From Synthetic Biology to Clinical Trials.Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors.Current treatment options of T cell-associated immunotherapy in multiple myeloma.Targeting cancer stem cells by using chimeric antigen receptor-modified T cells: a potential and curable approach for cancer treatment.Analysis of ROR1 Protein Expression in Human Cancer and Normal Tissues.Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines.Development of CAR T cells designed to improve antitumor efficacy and safety.Immunotherapy for infectious diseases in haematological immunocompromise.
P2860
Q26749139-A52EB4B9-1D51-439E-81D1-BFCC109567B0Q26753082-B6E07527-5221-46F1-9B16-A56FB366CF0BQ26775720-7E0CE43C-C4F6-425E-8598-D6B9A751C95AQ27027729-86C25F0E-6504-4334-9EB1-CD47A9F1D638Q28088526-59B0DFDB-B82D-4C50-B71A-C00E236D3197Q30764873-D9FAEE23-8B0F-416F-9234-ADCB4DCC3EF6Q33655849-B65565FA-1E54-47AA-9DF6-246136119420Q33796950-160CD1FA-3C6E-4A29-8B1B-80A9F3434634Q33823270-53C5F691-1337-4B99-90ED-F7CE0FB97674Q34432692-56ABFEB4-8671-4FCE-9AE3-4084D56C3BADQ34453846-36F7908E-4303-4AC9-93C0-BF7C21C78497Q35811921-5047946B-F394-4A17-A365-526EF4A5E5D8Q35818365-37C203ED-AE18-4B27-9A97-79D4B836D38BQ36408432-F43AEDDA-9941-435E-9ADC-2BDD4F1614F7Q37692134-426613C1-1E08-4BA9-B138-2F4EB091F3DFQ37717884-BFD9CCED-B465-430B-B7E0-30BDA4888A1CQ38267385-9E54DF26-81E6-412D-8C24-A2362362FB43Q38435415-CF4055C6-6710-4325-9572-FA83FE7C6911Q38531361-8A9926D3-2D0A-4C36-BFEC-5E3E93F5B0B2Q38600697-CAE10894-9E23-4400-996F-A6AC8551A210Q38632105-83B6C20E-A0A1-4498-A099-1328FE7467CFQ38741113-1DBBE59F-4FA0-4F57-9CB5-8BDC41FE4DFDQ38773361-25C4BA3A-B606-4220-91C5-BE4832DD2647Q38777742-3CD3EC97-EDE7-4866-8F4A-7D07FA978E44Q38786626-BC2F8C52-6E2C-4D7E-9691-16F58B576958Q38805082-F441DD6B-1DBA-4556-B068-040D846E9709Q38807514-BDF47936-55F8-4492-9DF8-341F06046FF3Q38822723-3EBA16B2-BF1D-413A-A973-49EF5BFEC243Q38828829-F67B5A2E-5A02-40FE-9FBD-3D5289AFC079Q38830813-A2991B46-7008-4803-A525-1234DB21F51EQ38912282-F270A395-3FE1-4F9C-AB5C-D93C798F7C49Q38913549-6DDD47CA-72FC-49E4-8525-719DB20A2156Q39037477-1317DDFA-6398-41B8-80A6-2AE02C9F3131Q39059681-B759F6C3-9975-4ABE-8371-A2BB93DA561BQ39102170-6213670F-7249-4E6A-B57B-516EC6059B1AQ39177087-653E2E7D-37DC-432D-934E-1A1DF407717EQ39182547-752A86AE-29B2-44D1-8EE1-CC7B05CA2F8BQ39189908-FA6FAB80-5B3F-4656-88ED-8DDD6DBFFAA8Q39200527-2849F3C0-0F92-4ACD-839A-F9A5E3C2DCABQ39215653-1BD4BAE5-CEF2-454F-A7D9-5A027252BF29
P2860
Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma
description
2013 nî lūn-bûn
@nan
2013 թուականին հրատարակուած գիտական յօդուած
@hyw
2013 թվականին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Combining a CD20 chimeric anti ...... ive immunotherapy for lymphoma
@ast
Combining a CD20 chimeric anti ...... ive immunotherapy for lymphoma
@en
Combining a CD20 chimeric anti ...... ive immunotherapy for lymphoma
@nl
type
label
Combining a CD20 chimeric anti ...... ive immunotherapy for lymphoma
@ast
Combining a CD20 chimeric anti ...... ive immunotherapy for lymphoma
@en
Combining a CD20 chimeric anti ...... ive immunotherapy for lymphoma
@nl
prefLabel
Combining a CD20 chimeric anti ...... ive immunotherapy for lymphoma
@ast
Combining a CD20 chimeric anti ...... ive immunotherapy for lymphoma
@en
Combining a CD20 chimeric anti ...... ive immunotherapy for lymphoma
@nl
P2093
P2860
P921
P1433
P1476
Combining a CD20 chimeric anti ...... ive immunotherapy for lymphoma
@en
P2093
Brian G Till
Carolina Berger
David M Spencer
Jinjuan Wang
Lihua E Budde
Michael C Jensen
Shani E Frayo
Shaunda A Brouns
Stanley R Riddell
P2860
P304
P356
10.1371/JOURNAL.PONE.0082742
P407
P577
2013-01-01T00:00:00Z